<DOC>
	<DOCNO>NCT00274131</DOCNO>
	<brief_summary>To evaluate efficacy safety long-term treatment pramipexole tablet ( BI Sifrol® ) Parkinson 's disease ( phase III study ) .</brief_summary>
	<brief_title>Long-term Administration Study SND 919 Tablets Parkinson 's Disease</brief_title>
	<detailed_description>The efficacy safety long-term treatment pramipexole ( BI Sifrol® ) evaluate Parkinson disease patient open-label non-controlled design . The treatment initiate 0.125 mg bid ( breakfast supper ) . The dose increase stepwise due caution regard symptom safety patient , 1.5 mg tid ( meal ) . The treatment period set 56 week , follow stepwise dosedecreasing period ( maximum 4 week ) . Study Hypothesis : Comparison ( ) :</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Patients diagnosis Parkinson 's disease ( include juvenile parkinsonism ) ( 1 ) Patients meet follow inclusion criterion 1 . Patients least 20 year age 2 . In outpatient either sex . 3 . Patients stage modify Hoehn Yahr severity scale Patients psychiatric symptom confusion , hallucination , delusion , excitement , delirium , abnormal behaviour . Patients subjective symptom derive orthostatic hypotension . Patients hypotension ( systolic blood pressure &lt; 100 mmHg ) Patients concomitant illness severe cardiac , renal , hepatic disease Patients current past history epilepsy Pregnant , possibly pregnant , lactating woman Patients receive investigational product receive investigational product within 6 month study . Patients judge incompetent give consent Others judge investigator coinvestigator ineligible subject .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>